Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

Astellas

Status and phase: Completed; Phase 3; Phase 2

Conditions: Diabetes Mellitus, Type II; Type 2 Diabetes Mellitus

Treatments: Drug: nateglinide

Study type: Interventional

Funder types: Industry

Identifiers

NCT00189774

026-CL-004

Details and patient eligibility

About

The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes mellitus under the treatment with pioglitazone

Exclusion criteria

• Patients who cannot follow the diet therapy and/or exercise therapy
• Type 1 diabetes mellitus

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind